Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939184 · ClinicalTrials.gov registry record · Phase 2
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 796
- Enrollment target
NCT01939184 is a Phase 2 study that has completed, run by Warner Chilcott. The registered enrollment target is 796 participants.
The verdict
NCT01939184, a Phase 2 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 796 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
Interventions
- OTHER Placebo
- DRUG WC3055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 796 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01939184
The ClinicalTrials.gov registry entry for NCT01939184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 796 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01939184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01939184 about?
NCT01939184 is a clinical study titled "Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia". The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
What is the current status of trial NCT01939184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 796 participants. The study started on 2013-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01939184?
The interventions under investigation include: Placebo (OTHER), WC3055 (DRUG).
Who is sponsoring clinical trial NCT01939184?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.